Stereoselective pharmacokinetics of stable isotope (+/-)-[ 13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity

Chirality

Volumn 23, Issue 10, 2011, Pages 904-909

  Thacker, David L ^a   Modak, Anil ^b   Nguyen, Phuong D ^a   Flockhart, David A ^a   Desta, Zeruesenay ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CAMBRIDGE ISOTOPE LABORATORIES INC   (United States)

Author keywords

breath test; genotype; pharmacokinetics; racemic

Indexed keywords

CYTOCHROME P450 2C19; PANTOPRAZOLE C 13; RADIOISOTOPE; UNCLASSIFIED DRUG; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; CARBON; PANTOPRAZOLE;

AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG METABOLISM; ELIMINATION REACTION; ENANTIOSELECTIVITY; ENZYME ACTIVITY; GENOTYPE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; STEREOCHEMISTRY; ADOLESCENT; ADULT; CHEMISTRY; CLINICAL TRIAL; ENZYME ASSAY; ENZYME SPECIFICITY; FEMALE; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; STEREOISOMERISM; YOUNG ADULT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; BREATH TESTS; CARBON ISOTOPES; CYTOCHROME P-450 CYP2C19; ENZYME ASSAYS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; STEREOISOMERISM; SUBSTRATE SPECIFICITY; YOUNG ADULT;

EID: 80053925395     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.21011     Document Type: Article

References (21)

1. Desta Z, Zhao X, Shin JG, Flockhart DA,. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-958. (Pubitemid 35168437)
2. Rosemary J, Adithan C,. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007; 2: 93-109. (Pubitemid 46729082)
3. Goldstein JA,. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-355. (Pubitemid 32939439)
4. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P,. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247. (Pubitemid 44497506)
5. Chang TK, Yu L, Goldstein JA, Waxman DJ,. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997; 7: 211-221. (Pubitemid 27290635)
6. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG,. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50: 2202-2210. (Pubitemid 38924398)
7. Li Y, Hou J, Jiang H, Wang D, Fu W, Yuan Z, Chen Y, Zhou L,. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica 2007; 92: 1246-1249. (Pubitemid 350144185)
8. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E,. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027-1030. (Pubitemid 29005826)
9. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
10. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L,. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
11. Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, Shimodozono Y, Morikawa N, Takeda Y, Yamada K,. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009; 34: 91-94.
12. Mandelli M, Tognoni G, Garattini S,. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 1978; 3: 72-91. (Pubitemid 8287275)
13. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, Snyder KA, Stevens SR, Rush AJ, Weinshilboum RM,. CYP2C19 variation and citalopram response. Pharmacogenet Genomics 2011; 21: 1-9.
14. Desta Z, Modak A, Nguyen PD, Lemler SM, Kurogi Y, Li L, Flockhart DA,. Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. J Pharmacol Exp Ther 2009; 329: 297-305.
15. Furuta T, Iwaki T, Umemura K,. [13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel. Eur J Clin Pharmacol 2010; 66: 457-463.
16. Furuta T, Kodaira C, Nishino M, Yamade M, Sugimoto M, Ikuma M, Hishida A, Watanabe H, Umemura K,. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Aliment Pharmacol Ther 2009; 30: 294-300.
17. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Ishizaki T,. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther 2001; 69: 108-113. (Pubitemid 32225410)
18. Andersson T,. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28. (Pubitemid 26238200)
19. Andersson T, Weidolf L,. Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 2008; 28: 263-279. (Pubitemid 351521381)
20. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Hakusui H, Yamamori S, Ishizaki T,. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997; 62: 619-628. (Pubitemid 28068065)
21. Tanaka M, Yamazaki H, Hakusui H, Nakamichi N, Sekino H,. Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole - a preliminary study. Chirality 1997; 9: 17-21. (Pubitemid 27149066)